HT-KIT significantly reduces tumor burden and induces cell death in preclinical GIST models by targeting KIT mutations. Rapid tumor cell death observed within 24 hours of HT-KIT treatment, with ...
NEW HAVEN, Conn.--September 28, 2015--Kolltan Pharmaceuticals, Inc. today announced the presentation of data from a preclinical study evaluating KTN0158 in dogs with spontaneous mast cell tumors.
Blockade of Platelet-Derived Growth Factor Receptor-Beta by CDP860, a Humanized, PEGylated di-Fab', Leads to Fluid Accumulation and Is Associated With Increased Tumor Vascularized Volume Activation of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback